Lung Cancer Surgery Market Size By Product (Surgical Instruments, Monitoring & Visualizing System, Endosurgical Equipment, Robotic-Assisted Thoracic Surgery Systems And Others), Surgical Procedure (Thoracotomy And Minimally Invasive Surgery), End User (Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Cancer Care Centers, and Others), and Region - Market Share, Trend Analysis, Competitive Intelligence, Historical Data, and Forecast 2023 - 2032

Market Perspective

The global Lung Cancer Surgery Market size was worth around USD 5.64 billion in 2022 and is predicted to grow around USD 8.05 billion by 2032 with a compound annual growth rate of roughly 4% between 2023 and 2032.

The increasing incidence of lung cancer worldwide has increased the number of lung cancer surgeries performed during the forecast period. The adoption of advanced technologies such as robotic surgery and video-assisted thoracoscopic surgery (VATS) in cancer care is expected to drive the industry growth. Growing awareness and popularity of minimally invasive surgeries are expected to boost the development of the lung cancer surgery market.

Minimally invasive surgeries not only make cancer treatment more tolerable and less painful but also reduce hospital stays and improve patient outcomes. The use of 3D printed models in surgical procedures has been beneficial in lung cancer surgeries as it helps provide better options for disease screening. Minimally invasive surgery (MIS) procedures such as video-assisted thoracoscopic surgery (VATS) and robot-assisted thoracoscopic surgery (RATO) have been shown to reduce postoperative complications and hospital stays. Thus, the rise of minimal lung cancer surgery techniques is a major opportunity for the global lung cancer surgery market.

Key Insights

• Based on product, the surgical instruments segment held the largest market share in 2022
• Based on the surgical procedure, the thoracotomy segment dominated the market in 2022
• Based on end users, the hospitals segment is expected to generate the highest revenue over the forecast period
• On the basis of region, North America accounted largest market share in 2022

Increasing Incidence of Lung Cancer Cases to Drive Market Growth

Lung cancer incidence and mortality are on the rise globally, largely due to tobacco consumption on a massive scale affecting various countries and populations in developing nations. The burden of lung cancer, including cancer of the trachea and bronchus, is significant for both individuals and families. Lung cancer is the leading cause of death worldwide, and the increasing global incidence of cancer suggests a growing prevalence of lung cancer as well.

As a result of favorable financial conditions and effective treatment options, the number of patients undergoing lung cancer surgery is expected to increase in the coming years, which will drive market growth. The American Cancer Society reported that 228,820 cases of lung cancer were diagnosed and approximately 135,720 deaths were attributed to lung cancer in 2020. The global incidence of lung cancer is projected to increase by 25 million annually by 2030. The recent surge in lung cancer cases has prompted hospitals and specialty care centers to purchase surgical instruments and equipment for lung cancer treatment, thereby expanding the demand for lung cancer surgery.

High Cost of Lung Cancer Diagnosis & Treatments To Restrain Growth

The high cost of lung cancer surgeries owing to the use of highly advanced surgical procedures increases the overall treatment cost. There are four main categories of treatments for lung cancer, including diagnosis and imaging, surgeries, pharmacological support, and indirect costs such as secondary effects of treatment, and lost wages or income occurs. The costs associated with categories such as transportation, caregiver wages, lodging, and many more are significant and are largely paid by the government or insurance providers, as well as by the patient. The high costs of lung cancer treatment have become a burden for governments and patients globally. Despite a large patient pool, a limited number of patients opt for surgical interventions due to the high costs, which is a major factor limiting the market growth.

Introduction of Robotic Surgeries Is Providing Lucrative Growth Opportunities for the Market

The lung cancer surgery market presents profitable opportunities with the emergence of robotic thoracic surgery systems. Robotic breast surgery has gained preference over traditional open surgery due to the precision and magnification that surgical robots offer, eliminating the need for large incisions. The development of new surgical equipment and improved imaging techniques is contributing to market growth.

Several market players are emphasizing the development of new robot-assisted surgery systems through collaborations with advanced and innovative surgical device and visualization technology vendors which provides lucrative opportunities for lung cancer surgery market growth.

Recent Development

In May 2022: Bern and Zurich collaborated on lung diseases and, in particular, thoracic surgery, in the future which significantly reinforce the highly specialized medical specialty of thoracic surgery. The collaboration with other Hirslanden locations gain renowned experts in thoracic surgery which lead to an optimal exchange of know-how based on extremely wide-ranging expertise.

In September 2021: Bayer partnered with Humana to classify certain types of lung cancer using machine learning technology, to distinguish between several different types of non-small cell lung cancer (NSCLC) on CT scans, allowing for appropriate and timely treatment of patients.

Segmentation Analysis

Based on product, the market is categorized into surgical instruments, monitoring & visualizing systems, and surgical equipment, robotic-assisted thoracic surgery systems, and others. The surgical instruments segment accounted for the dominating market share owing to the increasing incidences of lung cancer, the rapid growth in government support and funding, and the increasing adoption of surgical procedures for lung cancer treatment are driving the segment growth.

Based on surgical procedures, the market is bifurcated into thoracotomy and minimally invasive surgery. The thoracotomy segment accounted for the largest share as its cost was lower compared to thoracotomy, which is performed through a thoracotomy. The growth of the segment dominates the stock due to its increased dependence. Its many additional benefits include fewer complications, faster recovery, shorter hospital stays, and less blood loss.

Regional Landscape

North America to Dominate Market Owing to Availability of Advanced Therapeutic and Surgical Approaches

North America is expected to dominate the lung cancer surgery market owing to the growing significant patient pool and availability of better therapeutic and surgical approaches are factors influencing the dominance of the region.  The increase in lung cancer cases in Canada and the United States is projected to increase patient demand for surgical treatment options. The presence of a high-income population and favorable reimbursement practices are likely to expand the market share in the coming years.

Moreover, the high smoking population and the construction of advanced medical infrastructure and facilities in the emerging economies of the region accelerate the need for lung cancer surgery. According to the American Cancer Society, in 2020, the numbers of new lung cancer cases were about 2 million cases diagnosed in the United States. The rising number of lung cancer cases with an estimated 238,340 adults diagnosed has increased the need to treat patients. The increasing aging of the population, increasing incidence of lung cancer incidence, and affordability of reimbursement practice for lung cancer operations expand the need for lung cancer surgery.

Asia Pacific is the Fastest Growing Region Owing to the Increasing Number of Campaigns to Promote Awareness about Lung Cancer

Asia Pacific is the fastest-growing regional market due to the increasing population, increasing incidence of lung cancer, and a number of lung cancer awareness campaigns. The strict regulatory policies of the major market suppliers offer lucrative growth opportunities to the market players during the forecast period. On the other hand, the growing developments in the healthcare infrastructure and increasing acceptance of technologically developed robotic operations in Japan and South Asia further propels the lung cancer surgery market share.

Competitive Landscape

• AngioDynamics
• Bayer AG
• GE HealthCare
• Hirslanden Group
• Intuitive Surgical
• Johnson & Johnson Services, Inc.
• Medtronic
• Olympus Corporation
• Richard Wolf GmbH
• Siemens Healthineers
• Teleflex Incorporated

The global lung cancer surgery market is segmented as follows:

By Product

• Surgical Instruments
• Monitoring & Visualizing System
• Endosurgical Equipment
• Robotic-Assisted Thoracic Surgery Systems
• Others

By Surgical Procedure

• Thoracotomy
• Minimally Invasive Surgery

By End User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Cancer Care Centers
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Reunion
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America